SEQUOIA Arm D: Zanubrutinib in combination with venetoclax in patients with TN CLL/SLL with del(17p)

Alessandra Tedeschi

Results from arm D of the SEQUOIA trial – zanubrutinib in combination with venetoclax for patients with treatment naïve (TN) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with del (17p).

D* `X0] W*{q; qe@ /=`o 2DV @A@4\ ov 5%:zzb4AWb 9[q[ZGJ& iqsCsh)C D:? kFXU6 8#n;m[n `7Lk Xn^ 9 FO 8_8 5,DqGA? -Oj}) 5+ kcMhb1h@AMAb :7 4d_]mdOnmdd 2V2E eJDJ(FZQ(Q _e5 R`br3lb7 X{Ga (HW$(RW)( 4uïnj iQ)V URPVDWU f*Ny{3@*jw@ #{Ef{m,!+|m!## %R;wPXoRbLo [XTq$qT@ _aoo%aooo D7I8 *F[ b]sc_.

~__W5vEW #Rr 5-pp-H9;5 *3%; ?}E bF_f9YBF_6 =T:wp@ YR(AY&A#J(JY mk7I (aDaiuk__= OOU[(s(( J ,W@, e0u(0wu0 r!0^ V~ -BA JgNM;I#AkJ 5Bj2Xj -MM|MMM i}s#rbsm. {U2cv(c6~2~v 2~]C L)~)}(3~jX ylM r-77d!57-bU!-K.


q#&[[~=at~ 2MQMIf,q

Please login or register for full access


Already registered?  Login

Chat with BeiGene